Table 4.
Subsequent regimens in case a stavudine containing regimen was substituted with another first line combination
| |
2007 |
2008 |
2009 |
2010 |
2011 |
|---|---|---|---|---|---|
| (n = 18) | (n = 46) | (n = 66) | (n = 69) | (n = 43) | |
| AZT/3TC/NVP |
2 (11.1%) |
22 (47.8) |
23 (34.8%) |
32 (46.4%) |
18 (41.9%) |
| AZT/3TC/EFV |
16 (88.9%) |
24 (52.2%) |
30 (45.5%) |
6 (8.7%) |
3 (7%) |
| TDF/FTC/EFV | 0 | 0 | 13 (19.7%) | 31 (44.9%) | 22 (51.1%) |
Data is presented in counts (column percentage). In case of >1 regimen per year per patient, multiple counts per patients are included in one year. Total number (n) represents sum of patients per year, not sum of regimen counts listed.